Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cue Biopharma, Inc. - Common Stock (NQ:CUE)

0.7812 +0.0192 (+2.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cue Biopharma, Inc. - Common Stock

< Previous 1 2 3 Next >
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Host Investor Call
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Two February 2023 Scientific Conferences
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Chief Medical Officer Transition
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
From Cue Biopharma, Inc.
Via GlobeNewswire
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)
Via ACCESSWIRE
Cue Biopharma Reports Third Quarter 2022 Financial Results
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.